| Literature DB >> 31684906 |
Chuan Wang1, Yanan Li1, Yi Ji2.
Abstract
BACKGROUND: The use of oral (PO) antibiotics following a course of certain intravenous (IV) antibiotics is proposed in order to avoid the complications of IV medications and to decrease the cost. However, the efficacy and safety of sequential IV/PO antibiotics is unclear and requires further study.Entities:
Keywords: Antibiotics; Complication; Intravenous; Oral; Perforated appendicitis
Mesh:
Substances:
Year: 2019 PMID: 31684906 PMCID: PMC6827245 DOI: 10.1186/s12887-019-1799-6
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Fig. 1Flow chart of study selection
Characteristics of included studies
| Study | Study type | Sample size | Age (years, mean ± SD) | Type of antibiotic | Length of antibiotic therapy (days, mean ± SD) | NOS/JS |
|---|---|---|---|---|---|---|
| Henry E. Rice 2001 | RCT | IV/PO: 16 | 11.9 ± 3.9 | IV: Ampicillin & gentamicin sulfate & clindamycin/PO: amoxicillin-clavulanate | 10.1 ± 0.5 | 3 |
| IV: 10 | 12.5 ± 3.7 | IV:Ampicillin & gentamicin sulfate & clindamycin | 10.4 ± 1.3 | |||
| Obinna O. Adibe 2008 | OCS | IV/PO: 47 | 9.7 ± 0.52 | IV: Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam/PO: TMP-SMX & Metronidazole | 14 ± 0 | 8 |
| IV:102 | 8.8 ± 0.41 | IV:Ampicillin–Sulbactam & Gentamicin OR Ampicillin–Sulbactam | 14 ± 0 | |||
| Jason D. Fraser 2010 | RCT | IV/PO: 50 | 10.1 ± 4.6 | IV: Ceftriaxone & Metronidazole/PO: Amoxicillin-Clavulanate | ≥ 5 | 2 |
| IV: 52 | 9.7 ± 4.2 | IV:Ceftriaxone & Metronidazole | 7 ± 0 | |||
| Shannon N. Acker 2016 | OCS | IV/PO: 291 | 9.7 ± 4.1 | IV: Ceftriaxone & Metronidazole/PO: NA | NA | 8 |
| IV: 34 | 8.9 ± 4.5 | IV:Ceftriaxone & Metronidazole followed by other types for home antibiotic | NA | |||
| Tara J. Loux 2016 | OCS | IV/PO: 123 | 10.24 ± 4.3 | IV: Piperacillin-Tazobactam/PO: TMP-SMX & Metronidazole | 15.2 ± 8.4 | 7 |
| IV: 98 | 10.51 ± 4.4 | IV:Piperacillin-Tazobactam followed by other types for home antibiotic | 15.2 ± 8.5 | |||
| Michael R. Arnold 2018 | RCT | IV/PO: 38 | 10.1 ± 3.6 | IV: Ertapenem/PO: Amoxicillin-clavulanate | 10 ± 0 | 3 |
| IV: 44 | 12.3 ± 3.6 | IV:Ertapenem | 10 ± 0 |
RCT: Randomized controlled trial; OCS: Observational clinical study; IV: Intravenous; PO: Oral; NA: Not available; NOS: Newcastle-Ottawa Scale score; JS: Jadad score
Summary of the outcomes of included studies
| Study | Sample size | Postoperative abscess | Wound infection | Readmission |
|---|---|---|---|---|
| Henry E. Rice 2001 | IV/PO: 16 | 0 (0%) | 1 (6%) | NA |
| IV: 10 | 0 (0%) | 1 (10%) | NA | |
| Obinna O. Adibe 2008 | IV/PO: 47 | 2 (4.2%) | 0 (0%) | NA |
| IV: 102 | 2 (2%) | 2 (2%) | NA | |
| Jason D. Fraser 2010 | IV/PO: 50 | 10 (20%) | NA | NA |
| IV: 52 | 10 (19%) | NA | NA | |
| Shannon N. Acker 2016 | IV/PO: 291 | 11 (3.8%) | NA | 44 (15.1%) |
| IV: 34 | 1 (2.9%) | NA | 6 (17.6%) | |
| Tara J. Loux 2016 | IV/PO: 123 | NA | NA | 19 (15.4%) |
| IV: 98 | NA | NA | 8 (8.1%) | |
| Michael R. Arnold 2018 | IV/PO: 38 | 3 (7.9%) | 2 (5.3%) | 6 (15.8%) |
| IV: 44 | 5 (11.4%) | 1 (2.3%) | 6 (13.6%) |
IV: Intravenous; PO: Oral; NA: not available
Fig. 2Forest Plot showing the risk ratio for the occurrence of postoperative abscess in the intravenous/oral and intravenous groups
Fig. 3Forest Plot showing the risk ratio for the occurrence of wound infection in the intravenous/oral and intravenous groups
Fig. 4Forest Plot showing the risk ratio for the occurrence of readmission in the intravenous/oral and intravenous groups